You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.
The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.
Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.
The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.